TRML vs. BCRX, CGEM, TARS, FDMT, DNA, IMTX, AUTL, RLAY, INBX, and HUMA
Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include BioCryst Pharmaceuticals (BCRX), Cullinan Therapeutics (CGEM), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), Ginkgo Bioworks (DNA), Immatics (IMTX), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Inhibrx (INBX), and Humacyte (HUMA). These companies are all part of the "biological products, except diagnostic" industry.
Tourmaline Bio (NASDAQ:TRML) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Tourmaline Bio. MarketBeat recorded 6 mentions for BioCryst Pharmaceuticals and 4 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.46 beat BioCryst Pharmaceuticals' score of 1.22 indicating that Tourmaline Bio is being referred to more favorably in the media.
Tourmaline Bio has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.
Tourmaline Bio has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -58.69%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Tourmaline Bio's return on equity.
BioCryst Pharmaceuticals received 467 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 66.43% of users gave BioCryst Pharmaceuticals an outperform vote.
Tourmaline Bio presently has a consensus target price of $61.80, suggesting a potential upside of 264.39%. BioCryst Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 126.90%. Given Tourmaline Bio's higher possible upside, research analysts clearly believe Tourmaline Bio is more favorable than BioCryst Pharmaceuticals.
Tourmaline Bio has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Tourmaline Bio beats BioCryst Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Tourmaline Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tourmaline Bio Competitors List
Related Companies and Tools
